2-(4-Amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-ol

Catalog No.: 
ACVJMD953
CAS No.: 
842149-46-6
Molecular Formula: 
C10H9ClN6O2
Molecular Weight: 
280.67
2-(4-Amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-ol structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg95%$134.00In stockInquiry
100mg95%$237.00InquiryInquiry
250mg95%$383.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-(4-Amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-ol
IUPAC Name2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-ol
MDL No.MFCD22124544
Molecular FormulaC10H9ClN6O2
Molecular Weight280.67
SMILESCCN1C(=NC2=C(Cl)N=CC(O)=C12)C1=NON=C1N
InChI KeyWGKAFLLLVPMZQU-UHFFFAOYSA-N
Synonym2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-ol;1H-Imidazo[4,5-c]pyridin-7-ol, 2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-
CAS No.842149-46-6
PubChem CID57973895

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302
Precautionary Statement(s)
P280-P305+P351+P338

Synthetic Route by SureRoute

1. ACVJMD953 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACVJMD953 route product structure diagram
    ACVJMD953842149-46-6In Stock
Inquiry

2. ACVJMD953 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACVJMD953 route product structure diagram
    ACVJMD953842149-46-6In Stock
Inquiry

3. ACVJMD953 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACVJMD953 route product structure diagram
    ACVJMD953842149-46-6In Stock
Inquiry

Comments (0)